A study of utility of delta IgG as a prognostic marker in Guillain Barre Syndrome after IV immunoglobulin treatment
Keywords:
Delta IgG, Guillain Barre Syndrome, prognostic, Immunoglobulin treatmentAbstract
Background: Guillain-Barré syndrome (GBS) is an acute onset immune-mediated disease affecting the peripheral nerve also its root Plasma exchange(PE) and intravenous immuno globulin(IVIG) have given evidence for faster recovery in GBS(4). IVIG treatment is comparatively costly but hospital stay duration is reduced.Other options include corticosteroids but have not shown benefit. Mortality of GBS is around 3%. Around 20 % patients have persisting neurological deficits and one half of these have severe disability. After a standard dose of IVIg treatment, GBS patients show a large variation in pharmacokinetics of IgG, which may be related to clinical outcome. The therapeutic dose of IVIg for GBS was empirically set at 2g per kg body weight, based mainly on the clinical experience in patients with immune deficiencies. Not all patients of GBS, however, show a good recovery after this standard dose. IVIg clearance may depend on disease severity and vary between individuals, implying that this dose may be suboptimal for some patients who might need DOSE adjustments for others the standard dose might be sufficient. Aims and Objectives: To study and determine the serum DELTA IgG values and evaluate its utility in the prognosis of Guillain Barre Syndrome after IVIG treatment.
Downloads
References
Liu S, Dong C, Ubogu E. Immunotherapy of Guillain-Barré syndrome. Human Vaccines & Immunotherapeutics. 2018;9(18) :1-12.
Shrivastava M, Nehal S, Seema N. Guillain-Barre syndrome: Demographics, clinical profile & seasonal variation in a tertiary care centre of central India. Indian J Med Res. 2017;145(2):203-208.
SR S, MB S, M S, H K, SK B, S K et al. Guillain-Barré syndrome: clinical profile and management [Internet]. PubMed. 2020 [cited 9 November 2020]. Available from: https://www.ncbi.nlm.nih.gov/pubmed/26421004
. Walling AD, Dickson G. Guillain-Barré syndrome. Am Fam Physician. 2013 Feb 1;87(3):191-7.
Llewelyn CA, Hewitt PE, Knight RS, Amar K, Cousens S, Mackenzie J, et al. Possible transmission of variant Creutzfeldt‐ Jakob disease by blood transfusion. Lancet 2004;363(9407):417‐ 21.
Ernawati, E., Baso, Y. S., Hidayanty, H., Syarif, S., Aminuddin, A., & Bahar, B. (2022). The effects of anemia education using web-based she smart to improve knowledge, attitudes, and practice in adolescent girls. International Journal of Health & Medical Sciences, 5(1), 44-49. https://doi.org/10.21744/ijhms.v5n1.1831
Gürses N, Uysal S, Çetinkaya F, Íslek Í, Kalayci AG. Intravenous immunoglobulin treatment in children with Guillain‐ Barré syndrome. Scandinavian Journal of Infectious Diseases 1995;27(3):241‐ 3.
Doorn PA. What's new in Guillain‐ Barré syndrome 2007‐ 2008. Journal of the Peripheral Nervous System 2009;14(2):72‐ 4.
Doorn PA. What's new in Guillain‐ Barré syndrome 2007‐ 2008. Journal of the Peripheral Nervous System 2009;14(2):72‐ 4.
Bick S, Tschernatsch M, Karg A, Fuehlhuber V, Trenczek TE, Faltermeier K, et al. Intravenous immunoglobulin inhibits BAFF production in chronic inflammatory demyelinating polyneuropathy‐a new mechanism of action. Journal of Neuroimmunology 2013;256 (1‐ 2):84‐ 90.
Dalakas MC. The use of intravenous immunoglobulin in the treatment of autoimmune neuromuscular diseases: evidence‐ based indications and safety profile. Pharmacology & Therapeutics 2004;102(3):177‐ 93.
Suryasa, I. W., Rodríguez-Gámez, M., & Koldoris, T. (2022). Post-pandemic health and its sustainability: Educational situation. International Journal of Health Sciences, 6(1), i-v. https://doi.org/10.53730/ijhs.v6n1.5949
Yu Z, Lennon VA. Mechanism of intravenous immune globulin therapy in antibody‐ mediated autoimmune diseases. New England Journal of Medicine 1999;340(3):227‐ 8.
Published
How to Cite
Issue
Section
Copyright (c) 2022 International journal of health sciences
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Articles published in the International Journal of Health Sciences (IJHS) are available under Creative Commons Attribution Non-Commercial No Derivatives Licence (CC BY-NC-ND 4.0). Authors retain copyright in their work and grant IJHS right of first publication under CC BY-NC-ND 4.0. Users have the right to read, download, copy, distribute, print, search, or link to the full texts of articles in this journal, and to use them for any other lawful purpose.
Articles published in IJHS can be copied, communicated and shared in their published form for non-commercial purposes provided full attribution is given to the author and the journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
This copyright notice applies to articles published in IJHS volumes 4 onwards. Please read about the copyright notices for previous volumes under Journal History.
